Plain-English translation of NCT07229040 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether cilastatin, a kidney-protective medication, works as well as thiosulfate in protecting your kidneys during a specialized ovarian cancer surgery. The surgery involves removing tumors from your abdomen and then delivering heated chemotherapy (cisplatin) directly into the abdominal cavity. Both medications are designed to reduce kidney damage from the chemotherapy, and researchers want to see if the medication performs at least as well as the current standard treatment.
Cisplatin chemotherapy, while effective against ovarian cancer, can damage the kidneys — especially when delivered in high concentrations directly into the abdomen during surgery. This trial is exploring whether the medication offers better or equal kidney protection compared to the current standard, which could help more patients safely tolerate this powerful cancer treatment.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive the debulking surgery with heated intraperitoneal chemotherapy as planned by your cancer team. During or around the time of surgery, you will receive one of the two kidney-protective medications (either cilastatin or thiosulfate) — which one you receive will be randomly assigned, and neither you nor your doctors will know which until the trial ends. Your kidney function will be closely monitored before, during, and after surgery to measure how well each medication protects your kidneys.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Spain